Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity

European Journal of Pharmacology

Volumn 659, Issue 2-3, 2011, Pages 224-232

  Jing, Li ^a,b   Wu, Yingliang ^b   Wu, Jing ^a   Zhao, Jun ^a   Zuo, Daiying ^b   Peng, Shuangqing ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Doxorubicin; Metallothionein; Peroxiredoxin

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE KINASE; DOXORUBICIN; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; METALLOTHIONEIN; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 5; PEROXIREDOXIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; HEART PROTECTION; LIPID PEROXIDATION; MALE; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SINGLE DRUG DOSE;

ANIMALS; ANTIOXIDANTS; CARDIOTOXINS; CREATINE KINASE; DOXORUBICIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MALE; METALLOTHIONEIN; MICE; MYOCARDIUM; PEROXIREDOXINS; SEQUENCE DELETION;

EID: 79955928665     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.031     Document Type: Article

References (73)

1. Abel, J., de Ruiter, N., 1989. Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. Toxicol. Lett. 47, 191-196.
2. Alphey, M.S., Bond, C.S., Tetaud, E., Fairlamb, A.H., Hunter, W.N., 2000. The structure of reduced tryparedoxin peroxidase reveals a decamer and insight into reactivity of 2Cys-peroxiredoxins. J. Mol. Biol. 300, 903-916.
3. Bachur, N.R., Gordon, S.L., Gee, M.V., 1978. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res. 38, 1745-1750. (Pubitemid 8349723)
4. Bryk, R., Lima, C.D., Erdjument-Bromage, H., Tempst, P., Nathan, C., 2002. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science 295, 1073-1077. (Pubitemid 34132237)
5. Buzdar, A.U., Marcus, C., Blumenschein, G.R., Smith, T.L., 1985. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55, 2761-2765. (Pubitemid 15008311)
6. Cai, L., Tsiapalis, G., Cherian, M.G., 1998. Protective role of zinc-metallothionein on DNA damage in vitro by ferric nitrilotriacetate (Fe-NTA) and ferric salts. Chem. Biol. Interact. 115, 141-151.
7. Chae, H.Z., Kim, H.J., Kang, S.W., Rhee, S.G., 1999. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res. Clin. Pract. 45, 101-112.
8. Choi, H.J., Kang, S.W., Yang, C.H., Rhee, S.G., Ryu, S.E., 1998. Crystal structure of a novel human peroxidase enzyme at 2.0 Å resolution. Nat. Struct. Biol. 5, 400-406.
9. Chubatsu, L.S., Meneghini, R., 1993. Metallothionein protects DNA from oxidative damage. Biochem. J. 291, 193-198. (Pubitemid 23107770)
10. Davies, K.J., Doroshow, J.H., 1986. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261, 3060-3067.
11. Doroshow, J.H., 1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460-472. (Pubitemid 13193830)
12. Eaton, D.L., Toal, B.F., 1982. Evaluation of the Cd/hemoglobin affinity assay for the rapid determination of metallothionein in biological tissues. Toxicol. Appl. Pharmacol. 66, 134-142.
13. Ferrans, V.J., 1978. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. J. Cancer Treat Rep. 62, 955-961. (Pubitemid 8377895)
14. Greenstock, C.L., Jinot, C.P., Whitehouse, R.P., Sargent, M.D., 1987. DNA radiation damage and its modification by metallothionein. Free Radic. Res. Commun. 2, 233-239.
15. Hall, A., Karplus, P.A., Poole, L.B., 2009. Typical 2-Cys peroxiredoxins-structures, mechanisms and functions. FEBS J. 276, 2469-2477.
16. Hamer, D.H., 1986. Metallothionein. Annu. Rev. Biochem. 55, 913-951.
17. Hirotsu, S., Abe, Y., Okada, K., Nagahara, N., Hori, H., Nishino, T., Hakoshima, T., 1999. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. Proc. Natl Acad. Sci. U.S.A. 96, 12333-12338.
18. Iliskovic, N., Hasinoff, B.B., Malisza, K.L., Li, T., Danelisen, I., Singal, P.K., 1999. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol. Cell. Biochem. 196, 43-49.
19. Iwahara, S., Satoh, H., Song, D.X., Webb, J., Burlingame, A.L., Nagae, Y., 1995. Purification, characterization, and cloning of a heme-binding protein (23 kDa) in rat liver cytosol. Biochemistry 34, 13398-13406.
20. Jin, D.Y., Jeang, K.T., 2000. Peroxiredoxins in cell signaling and HIV infection. Antioxidant and Redox Regulation of Genes. Academic Press, pp. 381-407.
21. Jung, K., Reszka, R., 2001. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv. Drug Deliv. Rev. 49, 87-105.
22. Kägi, J.H., 1991. Overview of metallothionein. Methods Enzymol. 205, 613-626.
23. Kalyanaraman, B., Perez-Reyes, E., Mason, R.P., 1980. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim. Biophys. Acta 630, 119-130.
24. Kalyanaraman, B., Sealy, R.C., Sinha, B.K., 1984. An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. Biochim. Biophys. Acta 799, 270-275.
25. Kang, Y.J., Chen, Y., Yu, A., Voss-McCowan, M., Epstein, P.N., 1997. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest. 100, 1501-1506.
26. Kang, Y.J., Li, G., Saari, J.T., 1999. Metallothionein inhibits ischemia-reperfusion injury in mouse heart. Am. J. Physiol. Heart Cicr. Physiol. 276, H993-H997.
27. Kaul, N., Siveski-Iliskovic, N., Hill, M., Slezak, J., Singal, P.K., 1993. Free radicals and the heart. J. Pharmacol. Toxicol. Methods 30, 55-67.
28. Kim, H., Lee, T.H., Park, E.S., Suh, J.M., Park, S.J., Chung, H.K., Kwon, O.Y., Kim, Y.K., Ro, H.K., Shong, M., 2000. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J. Biol. Chem. 275, 18266-18270.
29. Kisucka, J., Chauhan, A.K., Patten, I.S., Yesilaltay, A., Neumann, C., Van Etten, R.A., Krieger, M., Wagner, D.D., 2008. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ. Res. 103, 598-605.
30. Kumar, D., Kirshenbaum, L.A., Li, T., Danelisen, I., Singal, P.K., 2001. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid. Redox Signal. 3, 135-145.
31. Lee, V., Randhawa, A., Singal, P.K., 1991. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am. J. Physiol. Heart Circ. Physiol. 261, H989-H995.
32. Matsushima, S., Ide, T., Yamato, M., Matsusaka, H., Hattori, F., Ikeuchi, M., 2006. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113, 1779-1786. (Pubitemid 43958471)
33. Mello-Filho, A.C., Chubatsu, L.S., Meneghini, R., 1988. V79 Chinese-hamster cells rendered resistant to high cadmium concentration also become resistant to oxidative stress. Biochem. J. 256, 475-479. (Pubitemid 19006010)
34. Merten, K.E., Feng, W., Zhang, L., Pierce, W., Cai, J., Klein, J.B., Kang, Y.J., 2005. Modulation of cytochrome c oxidase-Va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. JPET 315, 1314-1319. (Pubitemid 41635420)
35. Minotti, G., Cairo, G., Monti, E., 1999. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J. 13, 199-212.
36. Myers, C.E., McGuire, W.P., Liss, R.H., Ifrim, I., Grotzinger, K., Young, R.C., 1977. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165-167. (Pubitemid 8140036)
37. Nagy, N., Malik, G., Fisher, A.B., Das, D.K., 2006. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291, H2636-H2640.
38. Nogoceke, E., Gommel, D.U., Kiess, M., Kalisz, H.M., Flohe, L., 1997. A unique cascade of oxidoreductases catalyses trypanothione-mediated peroxide metabolism in Crithidia fasciculata. Biol. Chem. 378, 827-836.
39. Ohkawa, H., Ohishi, N., Yagi, K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358.
40. Olson, R.D., Mushlin, P.S., 1990. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4, 3076-3086.
41. Palmiter, R.D., Findley, S.D., Whitmore, T.E., Durnam, D.M., 1992. MT-III, a brain-specific member of the metallothionein gene family. Proc. Natl Acad. Sci. U.S.A. 89, 6333-6337.
42. Poole, L.B., Reynolds, C.M., Wood, Z.A., Karolus, P.A., Ellis, H.R., Li Calzi, M., 2000. AhpF and other NADH: peroxiredoxin oxidoreductases, homologues of low Mr thioredoxin reductase. Eur. J. Biochem. 267, 6126-6133.
43. Quaife, C.J., Findley, S.D., Erickson, J.C., Froelick, G.J., Kelly, E.J., Zambrowicz, B.P., Palmiter, R.D., 1994. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33, 7250-7259. (Pubitemid 24208763)
44. Rabelo, E., De Angelis, K., Bock, P., Fernandes, T.G., Cervo, F., Klein, A.B., Clausell, N., Irigoyen, M.C., 2001. Baroreflex sensitivity and oxidative stress in adriamycin induced heart failure. Hypertension 38, 576-580.
45. Rhee, S.G., Kang, S.W., Chang, T.S., Jeong, W., Kim, K., 2001. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52, 35-41. (Pubitemid 33769667)
46. Rhee, S.G., Chae, H.Z., Kim, K., 2005a. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 38, 1543-1552.
47. Rhee, S.G., Yang, K.S., Kang, S.W., Woo, H.A., Chang, T.S., 2005b. Controlled elimination of intracellular H(2)O(2): regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid. Redox Signal. 7, 619-626.
48. Sato, M., Bremner, I., 1993. Oxygen free radical and metallothionein. Free Radic. Biol. Med. 14, 325-337.
49. Schröder, E., Littlechild, J.A., Lebedev, A.A., Errington, N., Vagin, A.A., Isupov, M.N., 2000. Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7A resolution. Structure 8, 605-615. (Pubitemid 30409313)
50. Schröder, E., Brennan, J.P., Eaton, P., 2008. Cardiac peroxiredoxins undergo complex modifications during cardiac oxidant stress. Am. J. Physiol. Heart Circ. Physiol. 295, H425-H433.
51. Seo, M.S., Kang, S.W., Kim, K., Baines, I.C., Lee, T.H., Rhee, S.G., 2000. Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275, 20346-20354.
52. Shuai, Y., Guo, J.B., Peng, S.Q., Zhang, L.S., Guo, J., Han, G., Dong, Y.S., 2007. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol. Lett. 170, 66-74.
53. Singal, P.K., Iliskovic, N., 1998. Doxorubicin-induced cardiomyopathy. N. Eng. J. Med. 339, 900-905.
54. Singal, P.K., Kirshenbaum, L.A., 1990. A relative deficit in antioxidant reserve may contribute in cardiac failure. Can. J. Cardiol. 6, 47-49.
55. Singal, P.K., Deally, C.M., Weinberg, L.E., 1987. Subcellular effects of adriamycin in the heart: a concise review. J. Mol. Cell. Cardiol. 19, 817-828.
56. Singal, P.K., Iliskovic, N., Li, T., Kumar, D., 1997. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11, 931-936. (Pubitemid 27425894)
57. Siveski-Iliskovic, N., Kaul, N., Singal, P.K., 1994. Probucol promotes endogenous antioxidants and provides protection against adriamycin induced cardiomyopathy in rats. Circulation 89, 2829-2835. (Pubitemid 24173705)
58. Siveski-Iliskovic, N., Hill, M., Chow, D.A., Singal, P.K., 1995. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91, 10-15.
59. Sun, X.H., Zhou, Z.X., Kang, Y.J., 2001. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res. 61, 3382-3387. (Pubitemid 32695029)
60. Theocharis, S.E., Kanelli, H., Margeli, A.P., Spiliopoulou, C.A., Koutselinis, A.S., 2000. Metallothionein and heat shock protein expression during acute liver injury and regeneration in rats. Clin. Chem. Lab. Med. 38, 1137-1140.
61. Theocharis, S.E., Margeli, A.P., Koutselinis, A., 2003. Metallothionein: a multifunctional protein from toxicity to cancer. Int. J. Biol. Markers 18, 162-169.
62. Thornalley, P.J., Vasak, M., 1985. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim. Biophys. Acta 827, 36-44.
63. Trujillo, M., Clippe, A., Manta, B., Ferrer-Sueta, G., Smeets, A., Declercq, J.P., Knoops, B., Radi, R., 2007. Pre-steady state kinetic characterization of human peroxiredoxin 5: taking advantage of Trp84 fluorescence increase upon oxidation. Arch. Biochem. Biophys. 467, 95-106.
64. Tsutsui, H., Kinugawa, S., Matsushima, S., 2009. Mitochondrial oxidative stress and dysfunction in myocardial remodeling. Cardiovasc. Res. 81, 449-456.
65. Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Von Hoff, A.L., Rozencweig, M., Muggia, F.M., 1979. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717.
66. Wang, G.W., Kang, Y.J., 1999. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. JPET 288, 938-944. (Pubitemid 29254129)
67. Winterbourn, C.C., Hampton, M.B., 2008. Thiol chemistry and specificity in redox signaling. Free Radic. Biol. Med. 45, 549-561.
68. Wood, Z.A., Poole, L.B., Hantgan, R.R., Karplus, P.A., 2002. Dimers to doughnuts: redox-sensitive oligomerization of 2-cysteine peroxiredoxins. Biochemistry 41, 5493-5504. (Pubitemid 34429383)
69. Wood, Z.A., Schroder, E., Robin Harris, J., Poole, L.B., 2003a. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28, 32-40.
70. Wood, Z.A., Poole, L.B., Karplus, P.A., 2003b. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300, 650-653. (Pubitemid 36520591)
71. Wu, H.Y., Kang, Y.J., 1998. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart. JEPT 287, 515-520. (Pubitemid 29133648)
72. Xu, M.F., Tang, P.L., Qian, Z.M., Ashraf, M., 2001. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 68, 889-901. (Pubitemid 32168065)
73. Zhao, W., Fan, G.C., Zhang, Z.G., Bandyopadhyay, A., Zhou, X., Kranias, E.G., 2009. Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis. Basic Res. Cardiol. 104, 377-389.